The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
Open accessAbstract
Avibactam is a non-β-lactam β-lactamase inhibitor with a spectrum of activity that includes β-lactamase enzymes of classes A, C, and selected D examples. In this work acylation and deacylation rates were measured against the clinically important enzymes CTX-M-15, KPC-2, Enterobacter cloacae AmpC, Pseudomonas aeruginosa AmpC, OXA-10, and OXA-48. The efficiency of acylation (k2/Ki) varied across the enzyme spectrum, from 1.1 × 101 m−1s−1 for OXA-10 to 1.0 × 105 for CTX-M-15. Inhibition of OXA-10 was shown to follow the covalent reversible mechanism, and the acylated OXA-10 displayed the longest residence time for deacylation, with a half-life of greater than 5 days. Across multiple enzymes, acyl enzyme stability was assessed by mass spectrometry. These inhibited enzyme forms were stable to rearrangement or hydrolysis, with the exception of KPC-2. KPC-2 displayed a slow hydrolytic route that involved fragmentation of the acyl-avibactam complex. The identity of released degradation products was investigated, and a possible mechanism for the slow deacylation from KPC-2 is proposed.Background: Avibactam is a β-lactamase inhibitor with a broad spectrum of activity.Results: Kinetic parameters of inhibition as well as acyl enzyme stability are reported against six clinically relevant enzymes.Conclusion: Inhibition efficiency is highest against class A, then class C, and then class D.Significance: These base-line inhibition values across enzyme classes provide the foundation for future structural and mechanistic enzymology experiments. Avibactam is a non-β-lactam β-lactamase inhibitor with a spectrum of activity that includes β-lactamase enzymes of classes A, C, and selected D examples. In this work acylation and deacylation rates were measured against the clinically important enzymes CTX-M-15, KPC-2, Enterobacter cloacae AmpC, Pseudomonas aeruginosa AmpC, OXA-10, and OXA-48. The efficiency of acylation (k2/Ki) varied across the enzyme spectrum, from 1.1 × 101 m−1s−1 for OXA-10 to 1.0 × 105 for CTX-M-15. Inhibition of OXA-10 was shown to follow the covalent reversible mechanism, and the acylated OXA-10 displayed the longest residence time for deacylation, with a half-life of greater than 5 days. Across multiple enzymes, acyl enzyme stability was assessed by mass spectrometry. These inhibited enzyme forms were stable to rearrangement or hydrolysis, with the exception of KPC-2. KPC-2 displayed a slow hydrolytic route that involved fragmentation of the acyl-avibactam complex. The identity of released degradation products was investigated, and a possible mechanism for the slow deacylation from KPC-2 is proposed. Background: Avibactam is a β-lactamase inhibitor with a broad spectrum of activity. Results: Kinetic parameters of inhibition as well as acyl enzyme stability are reported against six clinically relevant enzymes. Conclusion: Inhibition efficiency is highest against class A, then class C, and then class D. Significance: These base-line inhibition values across enzyme classes provide the foundation for future structural and mechanistic enzymology experiments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kovach, M. E., Elzer, P. H., Steven Hill, D., Robertson, G. T., Farris, M. A., Roop, R. M., & Peterson, K. M. (1995) · Gene · doi:10.1016/0378-1119(95)00584-1 · Cited by 3,350
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Three Decades of β-Lactamase Inhibitors
Drawz, S. M., & Bonomo, R. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00037-09 · Cited by 1,709
Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention
Gupta, N., Limbago, B. M., Patel, J. B., & Kallen, A. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir202 · Cited by 1,033
The Behavior and Significance of Slow‐Binding Enzyme Inhibitors
Morrison, J. F., & Walsh, C. T. (1988) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470123072.ch5 · Cited by 840
Diversity, Epidemiology, and Genetics of Class D β-Lactamases
Poirel, L., Naas, T., & Nordmann, P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01512-08 · Cited by 632
Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor
Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R.-F., Hu, J., Kern, G., Walkup, G. K., & Fisher, S. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205073109 · Cited by 545
Self-citationCeftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
Zhanel, G. G., Lawson, C. D., Adam, H., Schweizer, F., Zelenitsky, S., Lagacé-Wiens, P. R. S., Denisuik, A., Rubinstein, E., Gin, A. S., Hoban, D. J., et al. (2013) · Drugs · doi:10.1007/s40265-013-0013-7 · Cited by 433
“Stormy waters ahead”: global emergence of carbapenemases
Patel, G., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00048 · Cited by 423
Bush, K., & Fisher, J. F. (2011) · Annual Review of Microbiology · doi:10.1146/annurev-micro-090110-102911 · Cited by 419
Proliferation and significance of clinically relevant β‐lactamases
Bush, K. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12023 · Cited by 337
Livermore, D. M., Mushtaq, S., Warner, M., Zhang, J., Maharjan, S., Doumith, M., & Woodford, N. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00756-10 · Cited by 261
One-Third-the-Sites Transition-State Inhibitors for Purine Nucleoside Phosphorylase
Miles, R. W., Tyler, P. C., Furneaux, R. H., Bagdassarian, C. K., & Schramm, V. L. (1998) · Biochemistry · doi:10.1021/bi980658d · Cited by 246
Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
Coleman, K. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.07.026 · Cited by 241
Critical involvement of a carbamylated lysine in catalytic function of class D β-lactamases
Golemi, D., Maveyraud, L., Vakulenko, S., Samama, J.-P., & Mobashery, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241442898 · Cited by 240
Lahiri, S. D., Mangani, S., Durand-Reville, T., Benvenuti, M., De Luca, F., Sanyal, G., & Docquier, J.-D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02247-12 · Cited by 230
Self-citationStructure Elucidation by NMR in Organic Chemistry: A Practical Guide
Breitmaier, E. (2002) · Wiley eBooks · doi:10.1002/0470853069 · Cited by 186
In vitro activity of AVE1330A, an innovative broad-spectrum non- -lactam -lactamase inhibitor
Bonnefoy, A. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh358 · Cited by 185
Inhibitor Resistance in the KPC-2 β-Lactamase, a Preeminent Property of This Class A β-Lactamase
Papp-Wallace, K. M., Bethel, C. R., Distler, A. M., Kasuboski, C., Taracila, M., & Bonomo, R. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00693-09 · Cited by 180
Stachyra, T., Levasseur, P., Pechereau, M.-C., Girard, A.-M., Claudon, M., Miossec, C., & Black, M. T. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp197 · Cited by 180
Aktaş, Z., Kayacan, C., & Oncul, O. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.09.012 · Cited by 169
Current Challenges in Antimicrobial Chemotherapy: Focus on β-Lactamase Inhibition
Bebrone, C., Lassaux, P., Vercheval, L., Sohier, J.-S., Jehaes, A., Sauvage, E., & Galleni, M. (2010) · Drugs · doi:10.2165/11318430-000000000-00000 · Cited by 159
Stachyra, T., Péchereau, M.-C., Bruneau, J., Claudon, M., Frère, J., Miossec, C., Coleman, K., & Black, M. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00568-10 · Cited by 145
Shahid, M., Sobia, F., Singh, A., Malik, A., Khan, H. M., Jonas, D., & Hawkey, P. M. (2009) · Critical Reviews in Microbiology · doi:10.1080/10408410902733979 · Cited by 131
New β‐lactam–β‐lactamase inhibitor combinations in clinical development
Shlaes, D. M. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12010 · Cited by 130
In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters
Mushtaq, S., Warner, M., & Livermore, D. M. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq306 · Cited by 129
New β-lactam antibiotics and β-lactamase inhibitors
Bush, K., & Macielag, M. J. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.515588 · Cited by 120
Livermore, D. M., Mushtaq, S., Warner, M., Miossec, C., & Woodford, N. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn320 · Cited by 120
Levasseur, P., Girard, A.-M., Claudon, M., Goossens, H., Black, M. T., Coleman, K., & Miossec, C. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06064-11 · Cited by 102
Improving known classes of antibiotics: an optimistic approach for the future
Bush, K. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.003 · Cited by 100
NXL104 Irreversibly Inhibits the β-Lactamase from Mycobacterium tuberculosis
Xu, H., Hazra, S., & Blanchard, J. S. (2012) · Biochemistry · doi:10.1021/bi300508r · Cited by 70
Luca, F. D., Benvenuti, M., Carboni, F., Pozzi, C., Rossolini, G. M., Mangani, S., & Docquier, J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110530108 · Cited by 69
Walkty, A. J., DeCorby, M. R., Lagacé-Wiens, P. R. S., Karlowsky, J. A., Hoban, D. J., & Zhanel, G. G. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01696-10 · Cited by 65
Papp‐Wallace, K. M., Taracila, M. A., Smith, K. M., Xu, Y., & Bonomo, R. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05769-11 · Cited by 53
FROM CHEMISTRY TO BIOCHEMISTRY TO CATALYSIS TO MOVEMENT
Jencks, W. P. (1997) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.66.1.1 · Cited by 53
Drawz, S. M., Taracila, M. A., Caselli, E., Prati, F., & Bonomo, R. A. (2011) · Protein Science · doi:10.1002/pro.612 · Cited by 51
Exploring the Inhibition of CTX-M-9 by β-Lactamase Inhibitors and Carbapenems
Bethel, C. R., Taracila, M. A., Shyr, T., Thomson, J. M., Distler, A. M., Hujer, K. M., Hujer, A. M., Endimiani, A., Papp‐Wallace, K. M., Bonnet, R., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00089-11 · Cited by 40
Dubreuil, L. J., Mahieux, S., Neut, C., Miossec, C., & Pace, J. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.02.013 · Cited by 26
Cited by
β-Lactams and β-Lactamase Inhibitors: An Overview
Bush, K., & Bradford, P. A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025247 · Cited by 1,412
β-Lactamases and β-Lactamase Inhibitors in the 21st Century
Tooke, C. L., Hinchliffe, P., Bragginton, E. C., Colenso, C. K., Hirvonen, V. H. A., Takebayashi, Y., & Spencer, J. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.002 · Cited by 1,016
Epidemiology of β-Lactamase-Producing Pathogens
Bush, K., & Bradford, P. A. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00047-19 · Cited by 938
Interplay between β-lactamases and new β-lactamase inhibitors
Bush, K., & Bradford, P. A. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0159-8 · Cited by 531
New β-Lactam–β-Lactamase Inhibitor Combinations
Yahav, D., Giske, C. G., Grāmatniece, A., Abodakpi, H., Tam, V. H., & Leibovici, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-20 · Cited by 521
Metadata
- Authors
- Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R.-F., Hu, J., Durand-Réville, T. F., Lahiri, S., Thresher, J., Livchak, S., Gao, N., Palmer, T., Walkup, G. K., & Fisher, S. L.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 288
- Issue
- 39
- Pages
- 27960-27971
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2091219913
- Cited by
- 372
- References
- 38
- FWCI
- 11.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.